CMND — Clearmind Medicine Share News
0.000.00%
Last trade - 00:00Brief: Clearmind Medicine Announces “Inside MEAI” Webinar Featuring New Insights From CMND-100 Psychedelic Clinical Trial
Brief: Clearmind Medicine Announces Filing Of European Patent Application For Novel Psychedelic Compounds For The Treatment Of Ptsd
NASDAQ RESUMED AT 09:45 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:40 AM
NASDAQ RESUMED AT 09:39 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:34 AM
U.S. STOCKS ON THE MOVE-BlackRock, MDA Space, Revolution Medicines
U.S. STOCKS ON THE MOVE-Bloom, J&J, CarMax
U.S. STOCKS ON THE MOVE-Tesla, Nano-X, Travere
Clearmind Medicine rises after alcohol addiction drug shows safety in early trial
Brief: Clearmind Medicine Announces Successful Completion Of Treatment Of Cmnd-100 For Alcohol Use Disorder
Brief: Clearmind Medicine Files Patent Application In India For Next-Gen Psychedelic Compounds To Treat Mental Health Disorders
SciSparc jumps as unit files patent for obesity, fatty liver treatment
U.S. STOCKS ON THE MOVE-Agricultural stocks, Papa John's, Oil companies
U.S. STOCKS ON THE MOVE-Nebius, Scienture, Clearmind
Clearmind rises after advancing trial of alcohol-use disorder drug
Brief: Clearmind Medicine Inc - Dsmb Approves Continuation Of Phase I/Iia Cmnd-100 Trial In AUD
Brief: Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile Of Cmnd-100 In Ongoing Phase I/Iia Clinical Trial
Brief: Clearmind Medicine Enters Development Agreement For Intranasal Formulation Of Proprietary Nonhallucinogenic Neuroplastogen MEAI